IMR Press / FBL / Volume 17 / Issue 1 / DOI: 10.2741/3917

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Review
Cooperative Hedgehog-EGFR signaling
Show Less
1 Division of Molecular Tumor Biology, Department of Molecular Biology, University of Salzburg, Salzburg, Austria
Front. Biosci. (Landmark Ed) 2012, 17(1), 90–99; https://doi.org/10.2741/3917
Published: 1 January 2012
Abstract

It has been known for many years that cooperative interactions between oncogenes (e.g. RAS, MYC, BCL2) can fuel cancer growth (1-5), but the restricted druggability of many of those interacting cancer genes has hampered translation of combined targeting to medical cancer therapy. The identification and characterization of cooperative cancer signaling pathways amenable to medical therapy is therefore a crucial step towards the establishment of efficient targeted combination treatments urgently needed to improve cancer therapy. Here we review recent findings of our group and colleagues on the molecular mechanisms of cooperative Hedgehog/GLI and Epidermal Growth Factor Receptor (EGFR) signaling, two clinically relevant oncogenic pathways involved in the development of many human malignancies. We also discuss the possible implications of these findings for the design of a therapeutic regimen relying on combined targeting of key effectors of both pathways.

Keywords
Hedgehog signaling
Epidermal growth factor receptor
GLI transcription factors
JUN/AP-1 transcription factors
MEK/ERK Signaling
Oncogenic Transformation
Cancer
Combination Therapy
Review
Share
Back to top